Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Daxor Corporation (Nasdaq: DXR) said the USPTO issued U.S. Patent No. 12,635,917 B2 for a “Remote Blood Volume Monitor.” The patent covers systems for continuous, remote tracking of absolute blood volume after a baseline test by combining Daxor blood-volume algorithms with subsequent hematocrit monitoring, including non-invasive wearable optical sensors (e.g., PPG). Daxor said it targets conditions such as heart failure, syncope, anemia, and polycythemia.
How this was made
The 30-second read
Why it matters
Issued patent can improve DXR’s defensibility and strengthen commercialization narratives for continuous monitoring in heart failure, syncope, anemia, and polycythemia—potentially supporting future partnerships and product expansion.
Market read
Company-specific IP milestone for DXR in remote blood volume monitoring; likely a sentiment-positive catalyst with incremental, not immediate, financial impact absent commercialization/regulatory details.
What to watch
Key gating items not addressed here include FDA labeling/clearance scope for the remote system, payer coverage/reimbursement, and whether the wearable sensor approach performs robustly across patient populations and device types.
Background
DXR develops blood volume analysis (BVA) diagnostics and now claims a patent for remote monitoring that anchors continuous non-invasive measurements (e.g., PPG wearables) to a precise baseline.
Ticker impact
Daxor (DXR) received a USPTO-issued patent for a remote blood volume monitor integrating wearable Hct sensing with its baseline algorithms.
Likely modest positive bias for DXR as investors price incremental product/market expansion optionality; magnitude depends on current valuation and follow-on regulatory/commercial milestones.
The article is a concrete, company-specific catalyst (issued patent) but does not include revenue, trial outcomes, FDA actions, or near-term contract wins that would typically drive a large repricing.
Market effects
Supports the broader remote patient monitoring/diagnostics theme, potentially improving sentiment toward companies developing non-invasive monitoring and algorithm-driven clinical decision support.
Limited; company is US-based and the patent is US-specific, so impact is primarily on DXR rather than regional peers.
Moderate; while the patent is US-issued, the underlying wearable/remote monitoring approach aligns with global digital health adoption trends.
Counterpoint
A patent alone may not translate into near-term adoption; clinicians may still require validation, reimbursement clarity, and workflow integration before meaningful sales ramp.
Key entities
- companyDaxor Corporation
NASDAQ-listed diagnostics company receiving USPTO patent for a remote blood volume monitoring system.
- regulatorUSPTO
US patent authority that issued the patent covering remote blood volume monitoring methods/systems.
